Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial

Although some intravenous drugs have been used to treat coronavirus disease 2019 (COVID-19), no effective antiviral agents are currently available in the outpatient setting. We aimed to evaluate the efficacy and adverse events of 14-day ciclesonide treatment vs. standard care for patients with mild-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical medicine 2021-08, Vol.10 (16), p.3545
Hauptverfasser:	Song, Joon-Young, Yoon, Jin-Gu, Seo, Yu-Bin, Lee, Jacob, Eom, Joong-Sik, Lee, Jin-Soo, Choi, Won-Suk, Lee, Eun-Young, Choi, Young-Ah, Hyun, Hak-Jun, Seong, Hye, Noh, Ji-Yun, Cheong, Hee-Jin, Kim, Woo-Joo
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthma Clinical medicine Clinical trials Consent Coronaviruses COVID-19 Disease transmission Drugs Enrollments Hospitals Inhalers Oxygen saturation Pneumonia Public health Respiratory failure RNA polymerase Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!